Recent Updates
Recently added Catalysts
HYFT Positive Sentiment Score: 70/100

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York AUSTIN, Texas, September 2nd, 2025 – ImmunoPrecise Antibodies Ltd. (the “Company” or

Tuesday, September 2, 2025 1 min read
Key Takeaway: ImmunoPrecise Antibodies Ltd. announced its participation in the 27th Annual H.C. Wainwright Global Investment Conference scheduled for September 8-10, 2025. Dr. Jennifer Bath, the company's President and CEO, will deliver a presentation and be available for one-on-one meetings with investors. This event represents a significant chance for the company to showcase its advancements and engage directly with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • ImmunoPrecise Antibodies is participating in a prominent investment conference.
  • Dr. Jennifer Bath will present the company's vision, enhancing visibility.
  • The event is an opportunity for valuable one-on-one meetings with investors.

Full Press Release Details

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York
AUSTIN, Texas, September 2nd, 2025 ImmunoPrecise Antibodies Ltd. (the Company or IPA ) (NASDAQ: IPA), today announced that it will participate in the 27th Annual H.C. Wainwright Global Investment Conference, taking place September 8th through September 10th, 2025.
Dr. Jennifer Bath, President CEO of IPA, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
-Conference: 27th Annual H.C. Wainwright Global Investment Conference
-Date: September 8-10th, 2025
Investors interested in scheduling a meeting with the IPA management team should contact their H.C. Wainwright representative or email meetings@hcwco.com
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutics company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies such as its LENSai platform to accelerate drug discovery and improve decision-making across complex biological systems. IPA supports global partners in advancing novel therapeutics, diagnostics, and translational research.
For more information, visit www.ipatherapeutics.com.
Louie Toma, CPA, CFA
Managing Director, CoreIR
investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.

Frequently Asked Questions

When will ImmunoPrecise participate in the conference?

ImmunoPrecise will participate in the conference from September 8th to 10th, 2025.

Who will represent ImmunoPrecise at the conference?

Dr. Jennifer Bath, President CEO of IPA, will represent the company.

How can investors schedule a meeting with IPA management?

Investors can contact their H.C. Wainwright representative or email meetings@hcwco.com.

What is the focus of ImmunoPrecise Antibodies Ltd.?

ImmunoPrecise focuses on discovering and developing next-generation biologics.

What technologies does ImmunoPrecise utilize?

The company uses proprietary technologies like its LENSai platform for drug discovery.

Tags: HYFT Viatris Investor Conferences Healthcare ImmunoPrecise Antibodies H.C. Wainwright investment conference biotherapeutics Dr. Jennifer Bath
Last updated: Sep 2, 2025